Abstract
Axsome Therapeutics will report first-quarter 2026 results Pre-Market on May 4, 2026; investors are watching revenue growth, loss trajectory, and late-quarter regulatory catalysts that could influence near‑term sentiment.Market Forecast
Consensus points to first-quarter revenue of 190.72 million US dollars, implying 59.11% year-over-year growth, with projected EPS at a loss of 0.87 US dollars and EBIT at a loss of 42.28 million US dollars, reflecting year-over-year improvements of 34.74% and 31.23%, respectively. While margin guidance for the current quarter is not available in the collected dataset, the company exited the prior quarter with a gross profit margin of 93.71% and a net profit margin of -14.57%, framing a high-gross-margin model that is still absorbing operating expense investments.The main business remains product revenue, which dominated the mix last quarter and is expected to continue to carry the topline as new prescriber adoption and broader utilization of key brands progress; royalties are a minor contribution and are not expected to materially alter mix near term. Within the portfolio, the most promising growth engine is the depression franchise anchored by AXS‑05 (Auvelity), with total company revenue expected to rise 59.11% year over year this quarter and last quarter’s product revenue estimated at 194.56 million US dollars (about 99.26% of revenue), underscoring where the bulk of growth is accruing.
Last Quarter Review
Axsome Therapeutics delivered fourth-quarter revenue of 196.00 million US dollars, up 65.03% year over year, with a gross profit margin of 93.71%, a GAAP net loss attributable to shareholders of 28.56 million US dollars for a net profit margin of -14.57%, and adjusted EPS of -0.56 US dollars, an improvement of 63.64% year over year. The quarter exceeded consensus on both the top line and EPS, with revenue of 195.999 million US dollars versus an estimate of 193.107 million US dollars and a per-share loss of 0.56 US dollars versus an estimated loss of 0.68–0.71 US dollars, reflecting better-than-expected operating leverage.Main business composition was highly concentrated in product sales, which accounted for approximately 194.56 million US dollars of the quarter’s revenue, with royalties contributing about 1.44 million US dollars, and the total topline growing 65.03% year over year on broader uptake of commercialized therapies.
Current Quarter Outlook
Main Business: Product Revenue Momentum and Mix
Consensus anticipates first-quarter revenue of 190.72 million US dollars, up 59.11% year over year but slightly below the fourth quarter’s 196.00 million US dollars, which suggests the market is baking in a degree of sequential moderation alongside continued robust annual growth. For a business model dominated by product revenue, quarterly patterns can be influenced by payer dynamics and the cadence of commercial initiatives; the full-year signal embedded in current estimates remains constructive despite sequential fluctuations. Given last quarter’s mix was approximately 99% products, the topline remains sensitive to prescription volume, gross-to-net adjustments, and access trends for the key brands.With a reported gross profit margin of 93.71% last quarter, the company’s cost of goods remains favorable for a portfolio of small-molecule assets, positioning gross profit to expand largely in line with product sales. The key swing factor is operating expenses, which are likely to stay elevated as the company continues to invest in field force, market education, and label-expansion workstreams. The implied EPS loss of 0.87 US dollars and EBIT loss of 42.28 million US dollars for this quarter both represent year-over-year improvements, indicating expectations for operating leverage as revenue scales, but the timing and magnitude will depend on the pace of prescriptions and the intensity of commercial and R&D spending during the period.
Most Promising Business: Auvelity and Indication Expansion
Auvelity remains the centerpiece growth driver for the company’s depression franchise, and it is central to the market’s expectation that total revenue grows 59.11% year over year this quarter. Analysts highlight Auvelity’s clinical and commercial profile as a differentiator and point to an additional near-term catalyst in Alzheimer’s disease agitation, for which a regulatory decision was guided to April 30, 2026; the outcome could shape both the addressable patient population and revenue trajectory. While segment-level revenue splits are not disclosed in the collected dataset, last quarter’s product revenue was approximately 194.56 million US dollars, and the Street’s view is that Auvelity is the most significant contributor to growth within that product mix.The potential label expansion into Alzheimer’s agitation represents a separate and sizeable demand pool that could augment prescriptions if approved, adding a new call point for the sales organization and further increasing the brand’s visibility. Institutional commentary also suggests that long-term revenue opportunity for the agitation use-case could be material if uptake is broad, though near-term estimates remain anchored in the existing depression indication until approvals and launch timelines are clarified. For this quarter’s print, investors are likely to scrutinize prescription trends, new prescriber additions, and refill dynamics as early signals of sustainable growth, with any updates on indication expansion timelines serving as secondary catalysts.
Key Stock Price Drivers This Quarter
The most immediate stock driver around the earnings event is the regulatory catalyst linked to AXS‑05 in Alzheimer’s disease agitation, with the decision scheduled for April 30, 2026; a positive or negative outcome may reframe near-term expectations for prescriptions and operating investment, and it could influence how investors interpret the revenue run-rate implied by the quarter. The topline print relative to the 190.72 million US dollars consensus, as well as any qualitative color on weekly prescription momentum, payer coverage, and patient adherence, will shape how the market extrapolates the second quarter. Margin commentary will matter: a high gross margin baseline allows operating leverage to emerge as SG&A growth normalizes, but guidance around commercialization spend and R&D cadence will dictate how quickly EPS narrows from the forecast loss of 0.87 US dollars.Pipeline and business development updates are an additional lever for sentiment. The agreement to obtain global rights to balipodect (a selective PDE10A inhibitor) adds optionality in schizophrenia and other neuropsychiatric conditions, but investors will look for clarity on development timelines and cost phasing to understand near-term P&L impact. Progress on the phase 3 program evaluating solriamfetol for major depressive disorder with excessive daytime sleepiness provides another potential future revenue stream; however, for the current quarter, the financial story remains concentrated in the commercial portfolio, led by Auvelity and supported by other marketed assets. Any incremental disclosures that refine prescriber adoption curves, duration of therapy, or market access could carry outsized influence on how the shares trade following the Pre-Market release on May 4, 2026.
Analyst Opinions
Bullish opinions dominate recent coverage. Across the collected period from January 1, 2026 to April 27, 2026, the ratio of bullish to bearish views is approximately 10:0, with multiple institutions reiterating Buy or Outperform ratings and raising or reaffirming price targets. Jefferies maintained a Buy rating with a 245 US dollars price target, citing continued conviction in execution and forward catalysts. UBS increased its price target to 259 US dollars and maintained a Buy, reflecting confidence in the revenue trajectory and the durability of the core portfolio. RBC Capital reiterated an Outperform and adjusted its target to 221–222 US dollars across recent notes, emphasizing that the market may be undervaluing the opportunity in Alzheimer’s disease agitation and that the core story remains compelling into the catalyst and the quarter.Mizuho Securities reaffirmed its Buy rating with a 217 US dollars target, underscoring expectations for ongoing growth from the commercial base while the pipeline advances. TD Cowen maintained a Buy and a 190 US dollars target, highlighting Auvelity’s best‑in‑class potential in agitation and continued commercial momentum as key pillars supporting the outlook. Needham reiterated a Buy and raised its target to 154 US dollars, with the rationale centered on strong performance metrics and strategic progress in broadening the company’s therapeutic footprint. William Blair kept an Outperform view, calling out solid commercial execution, a sufficient cash runway, and advancement of late‑stage programs as supportive to the investment case. H.C. Wainwright reaffirmed a Buy on expectations that strengthened product exclusivity and the late‑stage pipeline bolster multiyear growth prospects. Guggenheim kept a Buy stance with a 245 US dollars target, reinforcing the constructive thesis.
Taken together, the majority view expects first-quarter revenue of 190.72 million US dollars, year-over-year growth of 59.11%, and continued high gross margin underpinning an improving loss profile as operating leverage develops. Analysts broadly see Auvelity as the main driver of near-term growth with a potential incremental inflection if the Alzheimer’s agitation decision is favorable on April 30, 2026, and they flag that any commentary on prescription momentum, payer dynamics, and commercialization spend will be pivotal for how the shares trade after the release. The absence of bearish calls in the period and a clustering of targets between 190 and 259 US dollars signal a consensus leaning that the risk-reward remains positive into the print, contingent on both the catalyst outcome and confirmation of the revenue run-rate aligned with current forecasts.
Comments